Immunization with human papillomavirus (HPV) L1 virus-like particles (VLPs) prevents infection with HPV. However, the expense and logistical demands of current VLP vaccines will limit their widespread use in resource-limited settings, where most HPV-induced cervical cancer occurs. Live oral adenovirus vaccines have properties that are well-suited for use in such settings. We have described a live recombinant adenovirus vaccine prototype that produces abundant HPV16 L1 protein from the adenovirus major late transcriptional unit and directs the assembly of HPV16 VLPs in tissue culture. Recombinant-derived VLPs potently elicit neutralizing antibodies in mice. Here, we characterize the immune response to the recombinant after dual oral and intranasal immunization of pigtail macaques, in which the virus replicates as it would in immunized humans. The immunization of macaques induced vigorous humoral responses to adenovirus capsid and nonstructural proteins, although, surprisingly, not against HPV L1. In contrast, immunization elicited strong T-cell responses to HPV VLPs as well as adenovirus virions. T-cell responses arose immediately after the primary immunization and were boosted by a second immunization with recombinant virus. T-cell immunity contributes to protection against a wide variety of pathogens, including many viruses. The induction of a strong cellular response by the recombinant indicates that live adenovirus recombinants have potential as vaccines for those agents. These studies encourage and will inform the continued development of viable recombinant adenovirus vaccines.
L
ive adenovirus vaccines have been used by the United States military for decades to prevent adenovirus type 4 (Ad4)-and Ad7-induced severe upper respiratory disease in recruits (1) . Given orally as enteric-coated tablets, the vaccines contain lyophilized Ad4 and Ad7 that induce both humoral and cell-mediated immunity as they replicate asymptomatically in the gut of the vaccinee. With one dose, these vaccines confer long-lasting protection from Ad4 and Ad7 infection with great efficacy and exemplary safety (1) . The Ad vaccines possess properties that are wellsuited to the developing world, including low dosage and consequent economy of production, ease of administration, freedom from needles, and a single-dose regimen. Live recombinant adenoviruses (rAds) used in a similar manner might prove to be powerful tools for immunization against other pathogens, especially in low-resource settings.
Human papillomavirus (HPV) causes cervical cancer that kills about 275,000 women annually, predominantly in developing nations (http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx?cancer ϭcervix). Two HPV vaccines have been licensed: Gardasil and Cervarix, which both contain HPV16 and HPV 18 virus-like particles (VLPs) composed of recombinant L1, the HPV major capsid protein. Both vaccines prevent persistent HPV infection and cervical disease induced by the HPV types included in the vaccine (2) . However, about 80% of cervical cancer worldwide occurs in women in low-resource and/or remote settings who may never receive these vaccines, as the vaccines are costly and require multiple injections (3) . The development of an improved HPV vaccine therefore remains a high priority and an attractive opportunity for assessing the utility of a replicating adenovirus vaccine.
To explore the applicability of the live rAd platform to other pathogens, we constructed replication-competent adenovirus recombinants that make novel use of the high-level gene expression characteristic of the adenovirus major late transcriptional unit (MLTU) to produce papillomavirus L1 proteins (4) . Purified VLPs harvested from cells infected with a prototype expressing HPV16 L1 induced strong neutralizing-antibody responses in mice (4, 5) . L1 expression by these recombinants requires virus replication (4) , and responses to purified recombinant-derived VLPs in mice are therefore not likely to accurately predict responses to L1 produced by the recombinants as they replicate in a human vaccinee. Here, we characterize the immune responses of pigtail macaques to a prototype live recombinant HPV vaccine prepared using an Ad5 host range mutant that replicates in nonhuman primates. HPV exhibits strict host tropism and does not induce disease in monkeys. Therefore, we examined the immunologic surrogates used in humans and animal models in order to evaluate HPV L1 VLP vaccines (6) (7) (8) .
MATERIALS AND METHODS
Virus. Ad5hr-FFIL 16 (hr, host range; FFIL, fiber-fiber-internal ribosome entry site-L1) Fig. 1A ) has been described elsewhere (5) . The recombinant is fully replication competent, expresses the HPV16 L1 gene from the MLTU, and directs the assemblies of highly immunogenic HPV16 VLPs in tissue culture. The recombinant also carries the host range mutation hr404, which permits growth in monkey cells in culture and in macaques (9, 10) . Ad5hr-FFIL 16 titers were determined by plaque assay on 293 cells or by A 260 (1.5 ϫ 10 9 PFU/ml/A 260 [11] ). The purification of recombinants by CsCl density gradient centrifugation has been described (5) .
Immunizations. Four female pigtail macaques (Macaca nemestrina) were immunized with CsCl density gradient purified recombinants by a dual intranasal-intragastric protocol. At weeks 0 and 12, 2.5 ϫ 10 8 PFU of Ad5hr-FFIL 16 was delivered to each nostril in 250 l of phosphate-buffered saline (PBS), followed immediately by 5 ϫ 10 8 PFU administered to the stomach via a feeding tube (1 ϫ 10 9 PFU total) (9). The immunized monkeys were housed in isolation until viral DNA was no longer detected in the nasal and stool specimens. Following completion of the analysis of recombinant-induced immune responses at week 35, each animal also received 10 g of OptiPrep-purified baculovirus-derived HPV16 VLPs suspended in PBS plus 0.5 M NaCl injected into each deltoid muscle (20 g total).
Prior to and every 2 weeks after immunization, 5 ml of blood was drawn from each animal, clotted at room temperature, and incubated overnight at 4°C. Serum samples were collected, clarified, and stored at Ϫ80°C. Peripheral blood mononuclear cells (PBMCs) were purified as described previously (12) from 20 ml of blood drawn monthly and cryopreserved in 90% fetal bovine serum-10% dimethyl sulfoxide (DMSO). Serum samples and PBMCs were taken 7 and 21 days after the protein boost (Fig. 1B) .
PCR to detect viral DNA. Nasal secretions were obtained by swabbing both nostrils with sterile cotton-tipped sticks. The swabs were eluted in PBS containing 0.1% bovine serum albumin (BSA), 0.01% thimerosal, and 10 g/ml aprotinin and frozen at Ϫ80°C. PCR was performed on samples clarified by centrifugation (3 min at 10,000 rpm). Fresh stool samples were resuspended in a 10-fold volume of RPMI buffer supplemented with amphotericin B (Fungizone; LTI, Grand Island, NY), incubated at 100°C for 3 min, and clarified by centrifugation. Nested PCR of adenovirus fiber gene DNA and Southern blot confirmation were performed as described previously (9) .
Ad5 and HPV16 neutralization. Adenovirus-neutralizing antibody was measured by plaque reduction (5) . A 50% reduction compared to the no-serum controls was considered neutralizing. HPV16-neutralizing titers were determined by the secreted alkaline phosphatase method (13, 14) . For secreted embryonic alkaline phosphatase (SEAP) assays, a serum dilution of 1:50 was the lowest tested, as higher serum concentrations can nonspecifically interfere with the SEAP assay. Prior to immunization, the animals had no detectable Ad5-or HPV16-neutralizing antibodies.
Baculovirus-derived HPV16 L1 VLP production. VLPs were purified as described from SF9 cells infected with a recombinant baculovirus expressing HPV16 L1 (John Schiller, National Cancer Institute [NCI]) 72 h postinfection (13) . Control lysates from an irrelevant baculovirus recombinant were purified in parallel. VLP purity was estimated by Western blotting with rabbit anti-HPV16 polyclonal antibody.
Western blots. 293 cells (15) T-cell proliferation. Cultures of cryopreserved PBMCs were stimulated with baculovirus-generated HPV16 VLPs (10 or 1 g), a similarly prepared irrelevant baculovirus lysate (10 or 1 g), purified Ad5 virions (5 g), or phytohemagglutinin (PHA) (1 g), and proliferation was measured by the incorporation of [ 3 H]thymidine (17) . Stimulation index (SI) values were calculated by dividing the incorporated radioactivity of individual stimulated samples by the mean radioactivity of 6 unstimulated samples from the same day. The results of triplicate samples are listed as the mean SI values and their corresponding standard deviations. P values were calculated by a paired Student t test comparing postimmunization to preimmunization VLP10 SI values (P Ͻ 0.05 is considered significant). Cell viability is listed as a percentage and was determined by 7-aminoactinomycin (AAD) staining.
Alternatively, the PBMCs were suspended in 1 ml of PBS (pH 7.4), and 10 6 viable cells were incubated for 6 min at room temperature with carboxyfluorescein succinimidyl ester (CFSE) (3.3 g/ml). The cells were quenched, diluted with AIM-V medium containing 10% fetal bovine serum (FBS), plated, and stimulated as described above. After 5 days in culture, the cells were harvested and labeled with 7-AAD and allophycocyanin (APC) fluorescent antibodies (clone L200; BD Pharmingen). Proliferation data were acquired on a FACSCalibur (BD) machine and analyzed with CellQuest Pro software.
Institutional approval. All animal experiments were approved by the Johns Hopkins University Institutional Animal Care and Use Committee.
RESULTS

Ad5hr-FFIL
16 . Ad5hr-FFIL 16 ( Fig. 1A) is a member of a novel class of rAds that abundantly express exogenous genes from the adenovirus MLTU (5). Ad5hr-FFIL 16 carries a partially codonoptimized HPV 16 L1 gene inserted immediately downstream of the native fiber gene in late region 5 (Ad L5) of the MLTU, followed by an artificial polyadenylation signal. An intervening po- 16 Genomic structure and expression cassette. Line 1, the major late transcriptional unit (MLTU) of the adenovirus genome lies between the major late promoter (MLP) and early region 4 (E4). The primary ϳ27-kb transcript of the MLTU is alternatively polyadenylated and spliced to generate about 15 late mRNAs that comprise five late regions (Ad L1 to Ad L5) defined by the positions of their polyadenylation sites (arrowheads). Line 2, enlargement of the E3-fiber region of wild-type Ad5. In FFIL 16 (line 3), late region 5 (Ad L5) has been expanded to include a poliovirus IRES and the HPV16 L1 gene downstream of the native fiber gene. FFIL 16 also includes an E3 deletion of 2.8 kb (⌬E3) and a mutation in E2a (hr404; not shown) that confers the ability to grow in monkey cells. Both the fiber and L1 proteins are translated from a single L5 mRNA. (B) Immunization schedule. Blood samples were taken from animals to obtain PBMCs (^) and serum (*) at the times indicated. Monkeys were inoculated with 10 9 PFU of recombinant Ad5hr-FFIL 16 virus at day 0 and day 85. At day 237, the monkeys were given a protein booster consisting of 20 g of HPV16 L1 OptiPrep-purified VLPs made from recombinant baculovirus infections.
liovirus internal ribosome entry site (IRES) permits the expression of both fiber and L1 from a single bicistronic mRNA (5). A 2.8-kb sequence was deleted from E3 to accommodate the L1 gene, but unlike many rAd vaccine candidates, Ad5hr-FFIL 16 contains E1 and is viable in normal human cells. Finally, Ad5hr-FFIL 16 carries hr404, a point mutation that confers the ability to grow in monkey cells in culture and in macaques (9, 10) . Critically, such host range mutants are available only in Ad5 and Ad2 backgrounds, restricting this study approach to those serotypes.
Immunization of macaques. Four female pigtail macaques were immunized using a combination intranasal-intragastric protocol with a total of 1.0 ϫ 10 9 PFU of gradient-purified Ad5hr-FFIL 16 per monkey per immunization. Immunization and a specimen collection (Fig. 1B ) were performed essentially as described with viable recombinant Ad-simian immunodeficiency virus (SIV) vaccines in rhesus macaques (9) . The monkeys were weighed periodically, and complete blood counts were taken monthly. The vaccine was well tolerated, as judged by these parameters.
Ad5hr-FFIL 16 replication in macaques. Nested PCR (9) detected adenovirus DNA in the nasal swabs of all macaques, with two of four animals shedding for up to 10 days (Table 1) . Two animals had detectable virus in their stools after the first inoculation. The duration of shedding was similar to that of replicating Ad5hr-SIV vectors (9, 18) . Following the second immunization, virus was detected in the nasal secretions of one macaque and in the stools of two animals for 2 days. Southern blots of PCR products confirmed that the DNA amplified was viral. Nasal swab suspensions were also used to infect BSC-1 monkey kidney cells. Viral cytopathic effects (CPE) were observed in the cultures incubated with day-3 samples from macaques 811 and 831 (Table 1) . Recovered DNA was confirmed as Ad5hr-FFIL 16 by HindIII digestion of radiolabeled nucleic acid and sequencing (not shown). No other sample yielded virus.
Antibody response to the viral late nonstructural protein 100K. Viral DNA detected by PCR in nasal secretions or stool samples may originate from the inoculum. To confirm that Ad5hr-FFIL 16 replicated and expressed late genes, we sought an antibody response to the nonstructural viral late protein 100K. Like other viral late proteins, 100K expression is dependent upon virus replication. However, unlike the other viral late proteins, 100K is absent from mature virions. Therefore, antibodies to 100K can arise only in animals in which viral replication has occurred. Macaque serum samples were assessed for reactivity to 100K by immunoblotting the lysates of 293 cells transfected with a 100K expression plasmid (16) . Individual strips were incubated with preimmune serum and day 18 (d18) and d98 sera at a 1:50 dilution ( Fig. 2A) . Macaques 803 and 811 produced antibodies to 100K, which strongly supports that replication occurred in those animals. The response in 803 was evident on d18 and was maintained, while anti-100K antibody in 811 was first detectable at d98. Preimmune sera from macaques 746 and 831 reacted with a ϳ100K band in the lysates of untransfected cells, making it difficult to unequivocally detect 100K responses. The presence of the remaining viral late proteins in the virion and therefore in the inoculum precludes their use to assess replication in 746 and 831, and we can draw no firm conclusions concerning viral replication in those animals.
Neutralizing antibodies against Ad5. All four macaques developed anti-Ad5 neutralizing antibodies. Three macaques mounted a neutralizing response after the initial immunization (Fig. 2B) . The titers peaked at 3 to 4 weeks postimmunization and waned over the next 2 months. The boost with recombinant virus at d85 induced a response in the remaining seronegative macaque and elevated titers in the other animals 10-to 1,000-fold. Interestingly, macaque 831, which did not respond to the initial immunization, achieved the highest titer after the boost. Again, the titers fell after immunization but remained higher than those measured prior to the boost.
Adenoviral antibodies also were assessed by immunoblot and immunoprecipitation (IP) using serum samples obtained at days 18 and 112 (not shown). All macaques, including 831, mounted a response to the major capsid protein, hexon, by d18. Macaques 803 and 811 additionally responded to the external capsid protein penton or proteins penton and fiber, respectively, at d18. Following the boost, all monkeys maintained hexon reactivity with new or enhanced reactivity to the fiber, V (minor core), and inner capsid proteins VI and IIIa. Epitopes recognized in immunoblots or IPs may not be those targeted by neutralizing antibodies. However, increased anti-fiber antibodies correlated with the jump in neutralization titers following the boost, consistent with the role of the fiber protein in receptor attachment (19) . Ad5hr-FFIL 16 immunization and HPV16-neutralizing antibodies. Neutralizing antibodies induced by L1 protect against HPV infection (20) . HPV-neutralizing titers were determined at the peaks of the anti-adenovirus antibody responses after initial immunization (days 18 and 28) and immediately before and at the peak of the adenoviral response after the Ad5hr-FFIL 16 boost (days 85, 98, and 112) ( Table 2) . Remarkably, despite the immunogenicity of recombinant-produced VLPs in mice and of the adenoviral vector, no macaque developed HPV-neutralizing antibodies after Ad5hr-FFIL 16 immunization or boost. The absence of neutralizing antibody was confirmed by the lack of a detectable antibody response against HPV16 L1 in any of the macaques by enzyme-linked immunosorbent assay (ELISA), IP, or Western blots (not shown).
Our recombinants were designed with oral administration in mind. However, regimens involving a live rAd priming dose and subsequent purified protein boost have proved effective in inducing immune responses to SIV antigens in macaques and to influenza virus antigens in humans (21) (22) (23) . To determine whether the Ad5hr-FFIL 16 immunizations had primed a humoral response to HPV16 L1, each macaque was injected at week 35 with 10 g of purified HPV16 VLPs. Macaques 803 and 831 developed HPVneutralizing antibodies after VLP injection, suggesting that in those animals, the recombinant may have primed an L1 response ( Table 2) . Macaques 803 and 831 both also mounted an unequivocal Ad5 100K antibody response ( Fig. 2A) , which may indicate that recombinant replication was most vigorous in those macaques.
Macaques generate a strong T-cell response to L1 VLPs. Both replicating and replication-defective rAds induce strong T-cell responses. We investigated T-cell responses after Ad5hr-FFIL 16 immunization using a PBMC proliferation assay (17) . All animals mounted a robust T-cell response to L1 VLPs (Fig. 3 and Table 3 ). Following the first viral immunization, three of four animals (746, 803, and 811) had stimulation indices (SI) nearly 10-fold higher than their preimmunization levels when pulsed with 10 g/ml VLPs. Proliferation declined with time but remained above background in all three monkeys. After the Ad5hr-FFIL 16 boost at 3 months, the SI values rose again in macaques 746 and 811 while remaining largely unchanged for macaque 803. Monkey 831 displayed a delayed response to HPV VLPs: weak proliferation was seen at 28 and 56 days postimmunization followed by a strong response (SI, 12.6) at day 85 (prior to viral boost). Anti-adenovirus cell-mediated immunity was also induced by immunization and sustained throughout the study, with that of macaque 831 again being noticeably lower. Thus, replicating MLTU recombinants elicit robust cell-mediated responses to both viral and transgene products.
Following immunization with purified VLPs at day 247, macaques 803 and 831 showed an increase in T-cell responses to L1, with SIs 20-to 60-fold greater than those of the unstimulated controls. Macaque 746 remained unchanged from previously high levels, while 811 declined substantially from its peak (SI, 26.9) at day 112. None of the PBMCs of the animals were stimulated by the control baculovirus-infected cell lysate.
T-cell subset responses against L1 VLPs. To identify the cells that proliferate in response to L1 VLPs, CSFE-stained PBMCs from monkeys 803 and 811 obtained prior to immunization, after each virus administration (days 28 and 123), and after the VLP booster (d254) were stimulated with either VLPs or medium, stained with antibody against human CD4 and with 7-AAD, and examined by flow cytometry. Lymphocytes were selected based on forward and side scatter, and dead cells (7-AAD ϩ ) were excluded from the analysis. Figure 4 shows the lymphocytes obtained following the Ad5hr-FFIL 16 boost (day 112) in monkeys 803 and 811 after stimulation with HPV16 VLPs, which are representative of the other postimmunization PBMCs tested. CD4 ϩ lymphocytes do not proliferate in response to stimulation, but there was substantial CFSE dilution among CD4 Ϫ lymphocytes. Our anti-human CD8 antibody did not recognize the monkey CD8 antigen, and we could not directly measure proliferation of CD8 ϩ T cells. However, the position of these cells is consistent with the preferential proliferation of CD8 ϩ T cells in response to HPV16 L1 VLPs.
DISCUSSION
The replication-competent adenovirus recombinant Ad5hr-FFIL 16 expresses the HPV16 L1 protein from the adenoviral major late transcriptional unit (MLTU) and produces HPV L1 VLPs abundantly in tissue culture. Purified recombinant-produced VLPs are highly immunogenic when injected into mice (5), but mice do not support human adenoviral replication and do not permit an assessment of the recombinant in its intended application as a replicating vaccine. In this study, we have exploited a Adenoviruses are species specific, and human adenoviruses do not grow in most animals. Among the few exceptions are macaques, which support growth of host range (hr) mutants of the group C adenovirus serotypes Ad5 and Ad2 (9, 10) . The hr mutant/macaque model thus provides one of the few animal systems in which replicating adenovirus vaccine candidates can be evaluated. Importantly, no mutations similar to the host range mutants exist outside group C, and in particular, none is available in the Ad4 and Ad7 military vaccine types or in types under consideration as vaccine vectors because of low seroprevalence in humans (for example, Ad26 and Ad35 [24] ). Further, host range mutations affect a region of the viral 72-k DNA binding protein (DBP) that bears no recognizable sequence homology to that of viruses outside group C, preventing their reconstruction in other vaccine candidate serotypes. Therefore, our experimental approach is restricted to Ad5/Ad2. Seropositivity to Ad5 is widespread and can blunt the efficacy of replication-defective adenovirus vaccine candidates (25, 26) . Our replication-competent recombinants may be affected similarly. Therefore, it is important to stress that our Ad5 MLTU recombinants exploit viral gene expression strategies and genome architecture that are universal among adenoviruses, and that the construction of analogous MLTU recombinants in less seroprevalent adenoviral types should prove to be no major hurdle if necessary for the evasion of preexisting immunity.
Four female pigtail macaques were inoculated with Ad5hr-FFIL 16 by intranasal and intragastric routes to present the virus to mucosal surfaces (9, 27) . The prolonged detection of viral DNA in nasal swabs and stool samples, a vigorous neutralizing antibody response to Ad5, and development in two animals of antibodies to 100K, a late viral protein not present in the virion, confirmed replication in the monkeys.
We were surprised that despite its replication, the demonstrated potent immunogenicity of recombinant-derived HPV16 L1 VLPs and its induction of Ad5 antibody Ad5hr-FFIL 16 did not elicit HPV16 antibodies. The lack of a strong CD4 ϩ T-cell response after Ad5hr-FFIL 16 immunization is consistent with that result. It is generally accepted that antibodies but not cell-mediated responses, are protective against HPV infection (28) , and for that reason, it is not likely that the recombinant in its present form will be useful in the prevention of HPV infection.
The reasons for the puzzling failure of Ad5hr-FFIL 16 to elicit the anticipated antibody response are not clear. In mice immunized by intraperitoneal injection, a 5-fold mass excess of adenoviral particles completely inhibits the induction of antibodies by a dose of HPV16 VLPs that elicits high-titer antibodies if administered alone (M. G. Berg and G. Ketner, unpublished data). A similar phenomenon was observed in rabbits immunized with recombinant vesicular stomatitis viruses expressing HPV16 L1 (29) . Such immunological interference might explain the poor induction of HPV antibodies by Ad5hr-FFIL 16 in vivo. If so, increases in the stoichiometry of HPV VLPs to Ad5 particles might increase antibody induction. L1 production by MLTU recombinants varies widely depending on the specific regulatory elements used to drive expression (4). L1 production in vivo and immunogenicity therefore might be substantially improved by the use of different regulatory sequences in recombinant construction. Alternatively, the production of HPV L1 VLPs in vivo may be less than that expected from experiments in tissue culture. VLPs may not assemble efficiently in macaques, or the vigorous T-cell responses against infected cells might reduce VLP production by clearing VLP-producing cells prior to the release of the VLPs. Intracellular proteasomal degradation of L1 prior to VLP assembly and release might also preclude a strong B-cell response. In any of these cases, VLPs might fail to accumulate to levels in the local lymph nodes sufficient to activate antigen-specific B cells. The reported abilities of other live rAds to induce humoral immunity have been mixed. An SIV env recombinant elicited SIV-neutralizing antibody transiently after its second administration to macaques (9) , but an rAd expressing influenza A virus H5N1 hemagglutinin protein (30) failed to induce antibodies in humans after three immunizations (23) . Both of those recombinants primed an antibody response to subsequent immunization with purified protein. Notably, in both cases, the cell-mediated response to immunization with the recombinant included a CD4 ϩ T-cell response, which was not observed with Ad5hr-FFIL 16 . In contrast to the lack of a humoral response to L1, the cellular response induced by Ad5hr-FFIL 16 was robust. While a direct comparison to the published results for HPV VLP trials in humans of our in vivo results may be only suggestive, the cell-mediated response by Ad5hr-FFIL 16 substantially exceeds that generated in human volunteers to an HPV16 L1 VLP vaccine. Among 11 women given 3 doses of 50 g of VLPs, the mean SI of PBMCs by HPV16 L1 VLPs increased only 2-fold over their prevaccination mean values (7, 17) , while SI values rose Ͼ10-fold in each of our monkeys after one virus dose. T-cell responses to viable Ad7-HIV recombinants were of a magnitude similar to those seen here (9) . In women immunized with HPV16 L1 VLPs, both CD4 ϩ and CD8 ϩ cells expand in response to VLP stimulation (17) . We see no 
CD4
ϩ response, and for technical reasons, we could not confirm that CD8
ϩ T cells proliferated in our experiments. However, adenoviral vectors frequently generate strong CD8 ϩ T-cell responses (31), and we believe that the VLP-responsive T cells in immunized macaques were CD8 ϩ cells. It must be emphasized that there is no compelling evidence linking cell-mediated immunity to protection from HPV infection. However, in at least one study, L1 RNA was present in 100% of cervical cancer biopsy specimens, and CD8 ϩ T cells were as effective in killing tumor cells in vitro as were E7-specific cytotoxic T lymphocytes (CTLs) (32) , and in mice, immunization with L1 VLPs induced CD8 ϩ T-cell-mediated protection from challenge with HPV16-transformed cells that expressed a low level of L1 RNA and no detectable L1 protein (33) . Therefore, a T-cell response to L1 might contribute to protection in individuals immunized with an Ad5hr-FFIL 16 -like recombinant also optimized to increase antibody production.
The live oral military adenovirus vaccines safely induce vigorous humoral and cell-mediated responses and effective immunity against adenovirus-induced respiratory disease (1) . The low dose of live virus required, the ease and safety of needle-free delivery, and the single-dose regimen that would be offered by recombinant vaccines patterned on the Ad4/Ad7 vaccine model hold considerable promise for immunization, especially in the developing world. The lack of a humoral response to HPV 16 L1 in Ad5hr-FFIL 16 -immunized animals was therefore a disappointment in the context of HPV immunization. However, the cell-mediated response to HPV16 L1 in Ad5hr-FFIL 16 -immuized animals suggests that MLTU recombinants will be of value in immunization at least against pathogens for which cell-mediated responses are protective. These include many pathogens with an obligate intracellular stage, such as most viruses, intracellular bacteria (Mycobacteria and Francisella spp. [34] [35] [36] ), and parasitic protozoa (Plasmodium and Leishmania spp. [37, 38] ). Studies of live MLTU recombinants expressing other antigens may therefore extend the advantages of the safe, effective, and practical live military adenovirus vaccines to a variety of important pathogens if not, at the moment, to HPV.
